<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11624">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955615</url>
  </required_header>
  <id_info>
    <org_study_id>2016-002</org_study_id>
    <secondary_id>2016-000488-17</secondary_id>
    <nct_id>NCT02955615</nct_id>
  </id_info>
  <brief_title>ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)</brief_title>
  <acronym>LUPIL-2</acronym>
  <official_title>A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iltoo Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iltoo Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ILT-101 (human
      recombinant interleukin 2 (IL-2)) in patients with moderate to severe systemic lupus
      erythematosus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interleukin 2 (IL-2) plays an important role on immune homeostasis by acting on T
      lymphocytes. In systemic lupus erythematosus, there is a so called &quot;insufficiency&quot; in a
      subpopulation of T lymphocytes, the regulatory T cells (Tregs) leading to altered immune
      balance between regulatory and effector T cells. These cells seem to play a major role in
      the physiopathology of the disease. Many researches enlighten the fact that this Tregs/Teffs
      balance can be restored by administering low dose of IL-2. It is thus assumed that treatment
      with low dose of IL-2 may impact positively the progression of the disease and thus help
      patients improving their clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SRI-4 (SLE responder index)</measure>
    <time_frame>at week 12</time_frame>
    <description>Number of participants with SRI-4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From baseline up to week 24 or 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants able to reduce oral steroid dose of 25 and 50%</measure>
    <time_frame>From baseline to week 12 or 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti ds-DNA by immunology-based assay</measure>
    <time_frame>From baseline to week 12 or 24</time_frame>
    <description>Change in anti-dsDNA as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%Tregs</measure>
    <time_frame>From baseline to week 12 or 24</time_frame>
    <description>% change in Tregs as compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>ILT-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ILT-101</intervention_name>
    <description>Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.
SLE background therapy includes ...</description>
    <arm_group_label>ILT-101</arm_group_label>
    <other_name>Low dose IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Induction phase followed by weekly administrations of placebo on top of SLE background therapy.
SLE background therapy includes ...</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of SLE

          -  Active SLE

          -  On stable background therapy for 1 month

          -  Using highly effective contraception

        Exclusion Criteria:

          -  Serious organ failure (renal functional impairment, severe central nervous system
             manifestations, severe heart failure, liver failure)

          -  Any clinical evidence of active chronic infection HIV, hepatitis B, hepatitis C

          -  Clinical significant pleuritis or pericarditis

          -  Type1 Diabetes and/or CROHN's disease

          -  Use of Benlysta (belimumab) in the past 4 weeks

          -  Use of Rituximab in the past 6 months

          -  Vaccination with live attenuated virus in the last month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Klatzmann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique HÃ´pitaux de Paris (AP-HP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremie MARIAU</last_name>
    <email>j.mariau@iltoopharma.fr</email>
  </overall_contact>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 2, 2016</lastchanged_date>
  <firstreceived_date>October 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
